These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
211 related articles for article (PubMed ID: 21479319)
61. Nanomaterials and lung toxicity: interactions with airways cells and relevance for occupational health risk assessment. Bergamaschi E; Bussolati O; Magrini A; Bottini M; Migliore L; Bellucci S; Iavicoli I; Bergamaschi A Int J Immunopathol Pharmacol; 2006; 19(4 Suppl):3-10. PubMed ID: 17291399 [TBL] [Abstract][Full Text] [Related]
62. Review of health safety aspects of nanotechnologies in food production. Bouwmeester H; Dekkers S; Noordam MY; Hagens WI; Bulder AS; de Heer C; ten Voorde SE; Wijnhoven SW; Marvin HJ; Sips AJ Regul Toxicol Pharmacol; 2009 Feb; 53(1):52-62. PubMed ID: 19027049 [TBL] [Abstract][Full Text] [Related]
63. Modeling approaches for characterizing and evaluating environmental exposure to engineered nanomaterials in support of risk-based decision making. Hendren CO; Lowry M; Grieger KD; Money ES; Johnston JM; Wiesner MR; Beaulieu SM Environ Sci Technol; 2013 Feb; 47(3):1190-205. PubMed ID: 23293982 [TBL] [Abstract][Full Text] [Related]
64. Nanoparticles: a closer look at their dermal effects. Choksi AN; Poonawalla T; Wilkerson MG J Drugs Dermatol; 2010 May; 9(5):475-81. PubMed ID: 20480790 [TBL] [Abstract][Full Text] [Related]
66. Toxic potential of materials at the nanolevel. Nel A; Xia T; Mädler L; Li N Science; 2006 Feb; 311(5761):622-7. PubMed ID: 16456071 [TBL] [Abstract][Full Text] [Related]
68. Considerations when submitting nanotherapeutics to FDA/CDER for regulatory review. Tyner K; Sadrieh N Methods Mol Biol; 2011; 697():17-31. PubMed ID: 21116951 [TBL] [Abstract][Full Text] [Related]
69. The Life Cycle of Engineered Nanoparticles. González-Gálvez D; Janer G; Vilar G; Vílchez A; Vázquez-Campos S Adv Exp Med Biol; 2017; 947():41-69. PubMed ID: 28168665 [TBL] [Abstract][Full Text] [Related]
70. Historical overview of nanotechnology and nanotoxicology. Santamaria A Methods Mol Biol; 2012; 926():1-12. PubMed ID: 22975953 [TBL] [Abstract][Full Text] [Related]
71. Health implications of engineered nanomaterials. Pietroiusti A Nanoscale; 2012 Feb; 4(4):1231-47. PubMed ID: 22278373 [TBL] [Abstract][Full Text] [Related]
72. Evaluation criteria for the quality of published experimental data on nanomaterials and their usefulness for QSAR modelling. Lubinski L; Urbaszek P; Gajewicz A; Cronin MT; Enoch SJ; Madden JC; Leszczynska D; Leszczynski J; Puzyn T SAR QSAR Environ Res; 2013; 24(12):995-1008. PubMed ID: 24313439 [TBL] [Abstract][Full Text] [Related]
73. Guidance for safe handling of nanomaterials. Dhawan A; Shanker R; Das M; Gupta KC J Biomed Nanotechnol; 2011 Feb; 7(1):218-24. PubMed ID: 21485878 [TBL] [Abstract][Full Text] [Related]
74. [Safety assessment of nanomaterials in reproductive developmental field]. Yamashita K; Yoshioka Y Yakugaku Zasshi; 2012; 132(3):331-5. PubMed ID: 22382838 [TBL] [Abstract][Full Text] [Related]
75. Nanomaterial translocation--the biokinetics, tissue accumulation, toxicity and fate of materials in secondary organs--a review. Kermanizadeh A; Balharry D; Wallin H; Loft S; Møller P Crit Rev Toxicol; 2015; 45(10):837-72. PubMed ID: 26140391 [TBL] [Abstract][Full Text] [Related]
76. Health hazards associated with nanomaterials. Pattan G; Kaul G Toxicol Ind Health; 2014 Jul; 30(6):499-519. PubMed ID: 23012342 [TBL] [Abstract][Full Text] [Related]
77. Common nano-materials and their use in real world applications. McIntyre RA Sci Prog; 2012; 95(Pt 1):1-22. PubMed ID: 22574383 [TBL] [Abstract][Full Text] [Related]
78. National Survey of Workplaces Handling and Manufacturing Nanomaterials, Exposure to and Health Effects of Nanomaterials, and Evaluation of Nanomaterial Safety Data Sheets. Kim J; Yu IJ Biomed Res Int; 2016; 2016():8389129. PubMed ID: 27556041 [TBL] [Abstract][Full Text] [Related]